Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. China Biotech Services Holdings's Dividend Payout Ratio for the
months ended in Dec. 2025 was 0.00.
The historical rank and industry rank for China Biotech Services Holdings's Dividend Payout Ratio or its related term are showing as below:
HKSE:08037's Dividend Payout Ratio is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.49 * Ranked among companies with meaningful Dividend Payout Ratio only.
During the past 13 years, the highest Trailing Annual Dividend Yield of China Biotech Services Holdings was 3.85%. The lowest was 1.39%. And the median was 2.60%.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
China Biotech Services Holdings (HKSE:08037) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
China Biotech Services Holdings Dividend Payout Ratio Related Terms
China Biotech Services Holdings Dividend Payout Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Biotech Services Holdings Dividend Payout Ratio Chart
HKSE:08037 vs TMO, DHR, IDXX: Dividend Payout Ratio Comparison
For the Diagnostics & Research subindustry, China Biotech Services Holdings's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Biotech Services Holdings Dividend Payout Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, China Biotech Services Holdings's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where China Biotech Services Holdings's Dividend Payout Ratio falls into.
China Biotech Services Holdings Dividend Payout Ratio Calculation
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Biotech Services Holdings (HKSE:08037) has a Dividend Payout Ratio of 0.00 as of Dec. 2025. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on China Biotech Services Holdings and its competitors. According to the industry distribution chart, China Biotech Services Holdings ranks #999999 out of 54 companies in the Medical Diagnostics & Research industry.
Is China Biotech Services Holdings' Dividend Payout Ratio too high?
China Biotech Services Holdings' current Dividend Payout Ratio is 0.00. Based on the distribution chart, China Biotech Services Holdings ranks #999999 out of 54 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, China Biotech Services Holdings has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Biotech Services Holdings' Dividend Payout Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, China Biotech Services Holdings ranks #999999 out of 54 companies for Dividend Payout Ratio. This places China Biotech Services Holdings in the lower half of its industry. The industry median Dividend Payout Ratio is 0.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Medical Diagnostics & Research company?
The median Dividend Payout Ratio among Medical Diagnostics & Research companies is 0.49, based on 54 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on China Biotech Services Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Dividend Payout Ratio is 0.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Biotech Services Holdings's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Biotech Services Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Biotech Services Holdings (HKSE:08037) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.27, compared to a current price of HK$0.64 — trading 137% above its estimated fair value. The current Dividend Payout Ratio is 0.00. China Biotech Services Holdings' overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For China Biotech Services Holdings (HKSE:08037), the current Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Biotech Services Holdings (HKSE:08037) Overvalued in 2026?
Based on GuruFocus' analysis, China Biotech Services Holdings stock appears to be overvalued.
The current stock price of HK$0.64 is trading 137% above its estimated GF Value™ of HK$0.27.
GuruFocus considers China Biotech Services Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:08037:
Dividend Payout Ratio: 0.00
GF Value™: HK$0.27 vs. price of HK$0.64 (137% above fair value)
No single metric tells the full story. See the HKSE:08037 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Biotech Services Holdings Business Description
China Biotech Services Holdings Ltd is an investment holding company. It operates through five segments: Pharmaceutical Products, Medical and Health-Related Services, Immunotherapy, Insurance brokerage, BNCT, and Others. It derives prime revenue from the Medical & health-related services segment, which involves the provision of medical laboratory testing & health check services. The group has a business presence in Hong Kong & the PRC, of which key revenue is generated from Hong Kong. Immunotherapy-provision of tumor immune cell therapy & health management services. Pharmaceutical products-sale & distribution of health-related & pharmaceutical products. Insurance brokerage services. BNCT-provision of boron neutron capture therapy treatment services, & Others-provision of logistic services.
19GF Score
Get the complete analysis for HKSE:08037
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08037 has been successfully added to your 
